Has Melissa Reynoso received payments from drug or device companies?

Yes. Drug and device makers reported $4,667 in general payments to Melissa Reynoso across 229 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Melissa Reynoso did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Melissa Reynoso come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Melissa Reynoso

Family · Bakersfield, CANPI 1356018550

Payments from drug & device makers

$4,667in general payments, 2019–2025

Across 229 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$993
Regeneron Healthcare Solutions, Inc.$989
AstraZeneca$707
CSL Behring$276
Takeda Pharmaceuticals U.S.A., Inc.$272
Incyte Corporation$246
plus $1K from 18 others

What the payments were for

Food & beverage$4,47796%
Education$1914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	70	$993
Regeneron Healthcare Solutions, Inc.	43	$989
AstraZeneca	28	$707
CSL Behring	12	$276
Takeda Pharmaceuticals U.S.A., Inc.	14	$272
Incyte Corporation	10	$246
Novartis	11	$243
Ionis Pharmaceuticals, Inc.	8	$210
Blueprint Medicines Corporation	6	$142
Biocryst US Sales Co., LLC	5	$98
Phadia US Inc.	2	$86
Octapharma USA, Inc.	4	$73
Amgen	2	$48
ARS Pharmaceuticals Operations, Inc.	2	$45
Electromed, Inc.	2	$45
Kowa Pharmaceuticals America, Inc.	2	$34
Baxter Healthcare	1	$24
LEO Pharma Inc.	1	$24
Paratek Pharmaceuticals, Inc.	1	$22
Alk-abello, Inc	1	$22
Pfizer	1	$20
Pharming Healthcare, Inc.	1	$16
Grifols USA, LLC	1	$16
Genentech USA, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUCALA$125
AIRSUPRA$124

How this compares

$4,667 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
NucalaMepolizumab	26	$94,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	42	$29,418
Spiriva RespimatTiotropium Bromide	11	$5,859
Azelastine Hcl	96	$2,793
Albuterol Sulfate HfaAlbuterol Sulfate	52	$1,684
Ipratropium Bromide	50	$1,546
Wixela InhubFluticasone Propion/Salmeterol	14	$794
Fluticasone Propionate	49	$464
Montelukast Sodium	59	$399
Levocetirizine Dihydrochloride	33	$291
Triamcinolone Acetonide	27	$245
Famotidine	43	$147
Prednisone	12	$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKNucala, Trelegy Ellipta	$993	$124,02568 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Bakersfield

Jennifer TougasBakersfield$302K
Ashton ChaseBakersfield$86K
Lori RobertsonChino Hills$475K
Annette ShonLos Angeles$406K
Nancy GardettoSan Diego$394K
Lisa HigginsHanford$311K
Kim SchaferSacramento$288K
Dawn MeyerSan Diego$270K
Jennifer KangCerritos$255K
Jenine StoneEscondido$231K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →